Clinical trial NCT02073201: Development of Clinical Methods to Evaluate Neural Function in Aging
Official title: Development of Clinical Methods to Evaluate Neural Function in Aging
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Aging
Lead sponsor: University of Florida
Sponsor class: OTHER
Collaborators: name: National Institute on Aging (NIA)
First posted: 2014-02-27
Enrollment: 27
Sex: ALL
Minimum age (years): 20
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: We propose to recruit 30 persons over 60 years of age who are classified as either high- or low functioning based on performance on the Short Physical Performance Battery (SPPB). Participants with a SPPB score ≥ 11 will be categorized as high-functioning, while the low-functioning group will include participants with a SPPB score ≤ 8. We will also recruit 15 persons between 20-30 years of age. We will target cognitively intact (3MSE \> 80) older adults who are free of overt neuromuscular impairments (no dementias, brain tumors, major depression, history of stroke, etc.).

Brief summary: A primary focus of the University of Florida (UF) Claude D. Pepper Older Americans Independence Center (OAIC) is to build a comprehensive understanding of the causes and consequences of declining physical function and disability development among older adults. To date investigators have largely focused on sarcopenia, the age-related decline in skeletal muscle mass and strength, as the primary contributor to physical decline. However, recent findings indicate that changes in the central and/or peripheral nervous systems may play a larger role than previously thought in the development of functional limitations. These fields hold extensive promise for identifying novel contributors to age-related functional decline. Therefore, the overarching aim of this project is to develop the ability of RC1 to assess novel neural contributors to mobility and overall physical function. Importantly, the development of these techniques will provide the RC1 with the tools to evaluate the potential involvement of the central and peripheral nervous systems in age-related functional decline and disablement. The primary aim of this project is to develop techniques for quantifying peripheral motor unit number and size as well as spinal cord integrity.

Detailed description: As part of participation, the subjects will attend up to 4 visits. During the visits the following testing may occur:

* Vital signs (heart rate, blood pressure), height and weight will be measured.
* Tests that assess your mobility and questions about physical function. These tests are listed below and will not be conducted in a particular order, and will take approximately 1.5 hours to complete.

  * Walking tests,
  * Tests of physical ability that include:

    1. Standing up from chairs of different height
    2. Lying on the floor and rising to a standing position
    3. Kneeling on the floor and rising to standing position
    4. Climbing a flight of stairs
    5. Lift a weighted laundry basket and placing it on a shelf
  * Muscle strength tests will be performed on the legs and arms.
  * Questionnaires that address physical function.
  * Muscle and nerve testing will be done.
  * During the above testing, sensors will be worn on the forehead that use invisible light to indirectly measure blood flow and blood oxygen content of the brain. In addition, sensors may be worn the fingers that measure how the skin conducts electricity. A chest strap that measures heart beats will also be worn. These measures are safe and provide information about the nervous system responds to physical and/or mental challenges.
* Tests will be done that measure memory, attention, vocabulary, problem solving, and planning skills.
* A bone density and body composition measured (scanned) by the machine called DEXA. DEXA scans, like x-rays, are painless, and involve exposure to very small amounts of radiation.
* Images of the brain will be taken using magnetic resonance imaging (MRI). Magnetic resonance imaging (MRI) is a procedure that allows doctors to look inside the body by using a scanner that sends out a strong magnetic field and radio waves.

All of these test are done for this study and will not be used to diagnose or treat any medical problems.

The expected length of participation is approximately six hours total, over the course of 4 separate visits.

Eligibility criteria: Inclusion Criteria:

* Age 60 years and older OR 20-30 years
* Higher functioning older adults: Score ≥ 11 on the Short Physical Performance Battery (SPPB)
* Lower functioning older adults: Score ≤ 8 on the SPPB
* Body mass index: 20-35 kg/m2 to ensure homogeneity and strength of signal for EMG and MRI analyses
* Willingness to participate in all study procedures

Exclusion Criteria:

* Failure to provide informed consent;
* Contraindications to MRI, such as claustrophobia, heart pacemaker / defibrillator, heart valve prosthesis, aneurysm clip, metallic stent, neurostimulation system, cochlear implants or inner ear prosthesis, insulin pump or other infusion pump, metal slivers in the orbital area/eye socket
* active treatment for cancer or history of cancer in the past year
* Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest or stroke, use of a cardiac defibrillator, or uncontrolled angina;
* previous stroke with upper and/or lower extremities involvement within the last 6 months
* history of life-threatening cardiac arrhythmias, stroke, severe Parkinson's disease or severe neurological disorders likely to interfere with physical function
* renal disease requiring dialysis
* lung disease requiring steroids
* lower extremity amputation
* severe osteoarthritis or rheumatoid arthritis that interferes with physical function
* complicated diabetes requiring insulin
* A known diagnosis of dementia
* Unable to communicate because of severe hearing loss or speech disorder;
* Severe visual impairment, which would preclude completion of the assessments and/or intervention;
* Simultaneous participation in another intervention trial

Primary outcomes:
measure: Neuromuscular integrity by motor unit function
timeFrame: Baseline
Secondary outcomes:
measure: Structural integrity of the brain and spinal cord
timeFrame: Baseline
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: UF Clinical Translational Research Building
state: Florida
Study officials:
affiliation: University of Florida
name: Thomas Buford, PhD
role: PRINCIPAL_INVESTIGATOR
References: